Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transient 'NeoBRAF wild type' state in a patient with BRAFV600E mutant metastatic colorectal cancer.

Cytopathology : official journal of the British Society for Clinical Cytology - 1 Nov 2024

Cardone Claudia, Facchini Sergio, de Stefano Alfonso, Rachiglio Anna Maria, Avallone Antonio

Abstract excerpt

We report the case of a patient with a BRAFV600E mutant mCRC, with evidence of acquired 'NeoBRAF wild-type' (wt) state. The patient, longitudinally assessed by liquid biopsy, obtained a remarkable clinical outcome with a multimodal approach including surgery, systemic treatment and targeted therapy. In patients with newly diagnosed RAS and BRAFV600E mutant mCRC, longitudinal assessment with liquid biopsy is not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to Liquid Biopsy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 39086078
DOI: 10.1111/cyt.13429

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transient 'NeoBRAF wild type' state in a patient with BRAFV600E mutant metastatic colorectal cancer.PMID 39086078Read ↗

Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.Semantic proximity Read ↗

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancerSemantic proximity Read ↗

Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer.Semantic proximity Read ↗

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal CancerSemantic proximity Read ↗

Acquired resistance to BRAF inhibitory treatments requires tumor tissue remodeling and reveals targetable vulnerabilities in colorectal cancerSemantic proximity Read ↗

Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E mutation: A case report.Semantic proximity Read ↗

Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment.Semantic proximity Read ↗

Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report.Semantic proximity Read ↗

Concordance of Acquired Mutations between Metastatic Lesions and Liquid Biopsy in Metastatic Colorectal Cancer Treated with Anti-EGFR TherapySemantic proximity Read ↗

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer.Semantic proximity Read ↗

Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal CancerSemantic proximity Read ↗

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.